$BVXV Overreaction to Phase 3 Trial Anticipating $20 PT
Dropped from $40 to $3 on Phase 3 trial failure wasn’t even an FDA denial. Has facilities and will be focusing on other trials. Total overreaction. PT $20+
The study’s primary safety endpoint was also met.
The study’s primary safety endpoint was also met.
관련 발행물
면책사항
이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.